Announcement: New Pancreatic Cancer Drug Daraxonrasib Shows Promise in Phase 2 Trial

GMJ
By
Prof. Giorgi Pkhakadze
0 Min Read
Medical illustration of pancreatic cancer treatment research and targeted therapy development
A phase 2 trial published in NEJM shows promise for daraxonrasib, a novel targeted therapy for previously treated metastatic pancreatic cancer. The study compared the new drug to standard chemotherapy in this challenging patient population. — Photo: Tara Winstead / Pexels
1 min read|43 words

Breaking: New targeted therapy daraxonrasib shows promise for metastatic pancreatic cancer in phase 2 trial published in NEJM. Study compared the novel drug to standard chemotherapy in previously treated patients. Important step forward for this challenging disease.

Read the full article on GMJ Newsroom →

Was this article helpful?

Share This Article
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Why women’s brains lose omega-3 protection: new insights from European Alzheimer’s study

A 2025 study in Alzheimer's & Dementia identifies a sex-specific mechanism: women…

Creatine in Children With Brain Injury: Evidence Contradicts Safety Fears

A 20-year body of controlled trials demonstrates that creatine supplementation is safe…

How Exercise Rebalances Muscle Aging at the Cellular Level

Exercise suppresses DEAF1, a transcription factor that becomes overactive with age and…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like